Anti-CTLA-4 antibody exerts anti-tumor effects through blocking the CTLA-4-mediated immunosuppressive function of Tregs and depleting Tregs by Fc-mediated antibody-dependent cellular cytotoxicity and phagocytosis.36 Indeed, dual targeting PD-1 and CTLA-4 showed promising efficacy and favorable tolerability in advanced stage solid tumors like cervical cancer and NSCLC.37,38. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.